If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Directorate Changes

24 Oct 2014 07:00

RNS Number : 1755V
Imperial Innovations Group plc
24 October 2014
 



24 October 2014

 

Imperial Innovations Group plc

 

Directorate Changes

 

Imperial Innovations Group plc (AIM: IVO or 'the Group', 'Innovations') announces that its non-executive director Dr Paul Atherton will not be seeking re-election at the Group's AGM on 16 December 2014 and will step down from the Board as of that date.

 

Dr Atherton was appointed to the Board on 29 April 2006, having been a director of the Group's subsidiary Imperial Innovations Ltd since September 2004. Dr Atherton currently serves on the Nomination Committee of the Board and previously served on its Remuneration and Audit Committees.

 

Separately, in accordance with its policy of voluntary compliance with the UK Corporate Governance Code, the Group has appointed non-executive director Linda Wilding to the role of Senior Independent Director with immediate effect.

 

Martin Knight, Chairman of Imperial Innovations, said:

 

"On behalf of the Board I would like to thank Paul for his ten years of service, during which he has played an important and influential role in the evolution of the Group. His experience as a successful scientific entrepreneur and the chairman of technology businesses has ensured that the perspective of founders and managers remains central to our way of doing business.

 

"In addition to his role on the board of Innovations, Paul co-founded and chaired two of our spin-out companies. Midaz Lasers was successfully sold to Coherent Inc. in 2012, and Paul continues as the chairman of Nexeon, our largest unquoted investment.

 

"We look forward to continuing to work together with Paul and thank him for the significant contribution he has made to Innovations over many years."

 

For further information contact:

 

Imperial Innovations Group plc

020 3053 8834

Martin Knight, Chairman

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell

 

J.P. Morgan Cazenove (Nominated Adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Andy Roberts/Christopher Golden

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAKEDASPLFFF
Date   Source Headline
7th Jun 20177:00 amRNSForm 8 (OPD) IP Group PLC
6th Jun 201711:19 amRNSForm 8.3 - Touchstone Innovations
5th Jun 201712:46 pmRNSForm 8.3 - Touchstone Innovations Plc
1st Jun 20172:41 pmBUSForm 8.3 - Touchstone Innovations plc
1st Jun 20177:00 amRNSChairman's letter to shareholders
31st May 20175:58 pmRNSForm 8.5 (EPT/RI) - Touchstone Innovations Plc
31st May 201712:01 pmRNSForm 8.3 - Touchstone Innovations Plc
30th May 20177:00 amRNSForm 8.3 - Touchstone Innovations Plc
26th May 201712:29 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:15 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:14 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:10 pmRNSForm 8.3 - IP Group Plc
24th May 20172:55 pmRNSForm 8.3 - IP Group plc
24th May 20172:52 pmRNSForm 8.3 - Touchstone Innovations plc
24th May 20172:51 pmRNSForm 8.3 - IP Group Plc
24th May 20172:41 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 20171:15 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 201711:17 amBUSForm 8 (DD) - Touchstone Innovations Plc.
23rd May 201712:05 pmRNSUpdate on possible offer
23rd May 201711:45 amRNSForm 8.3 - Touchstone Innovations Plc
23rd May 201710:33 amRNSStatement re Possible Offer
23rd May 20177:01 amRNSStatement re Possible Offer
21st Apr 201711:21 amRNSInnovations invests £2.9m in Abzena placing
6th Apr 20177:00 amRNSInnovations provides seed funding for Cardian
31st Mar 20177:00 amRNSHalf Yearly Report
20th Mar 20177:05 amRNSInnovations supports funding round in Pulmocide
16th Mar 20177:00 amRNSInnovations invests in Cell Medica funding round
14th Mar 20177:00 amRNSInnovations supports funding round in Resolver
6th Mar 20177:00 amRNSInnovations leads £12m funding round in Garrison
28th Feb 201711:11 amRNSNotice of Results
21st Feb 20177:03 amRNSCell Medica granted FDA Fast Track designation
26th Jan 20172:00 pmRNSDirectorate Change
5th Jan 20177:00 amRNSChange of name to Touchstone Innovations plc
4th Jan 20179:00 amRNSAppointment of Joint Broker
20th Dec 201612:03 pmRNSPsiOxus signs exclusive licence agreement with BMS
28th Nov 20167:02 amRNSPortfolio company TopiVert receives IND approval
23rd Nov 20165:56 pmRNSGrant of share options
21st Nov 201612:53 pmRNSResult of AGM
28th Oct 201612:30 pmRNSProposed change of name to Touchstone Innovations
28th Oct 201612:29 pmRNSPosting of Annual Report and Notice of AGM
24th Oct 20167:12 amRNSVeryan announces completion of subject enrolment
13th Oct 20167:00 amRNSFinal Results
10th Oct 20161:02 pmRNSCrescendo Biologics sign collaboration with Takeda
6th Oct 20167:02 amRNSFirst patients dosed in TopiVert's Phase IIa study
3rd Oct 201612:10 pmRNSSale of Innovations portfolio company Permasense
21st Sep 20167:06 amRNSInnovations invests £5.1m in Artios Pharma Limited
14th Sep 201612:02 pmRNSNotice of Results
13th Sep 20164:08 pmRNSTR-1: Notification of major interest in shares
9th Sep 20161:15 pmRNSHolding(s) in Company
6th Sep 20164:17 pmRNSEdison issues update on Imperial Innovations (IVO)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.